Private Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Private Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$218K	Hold	350	–	–	0.02%	70
2026 Q1	$270K	Hold	350	–	–	0.03%	64
2025 Q4	$270K	Buy	+350	New	+$238K	0.03%	65
2025 Q3	–	Sell	-616	Closed	-$323K	–	87
2025 Q2	$323K	Buy	+616	New	+$344K	0.04%	67
2013 Q4	–	Sell	-4,820	Closed	-$1.51M	–	111
2013 Q3	$1.51M	Sell	4,820 -4,430	-48%	-$1.17M	0.55%	59
2013 Q2	$2.08M	Buy	+9,250	New	+$2.15M	0.77%	55

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Private Capital Advisors's REGN Position: Q2 2026 in Review

Private Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 350 shares worth $218K. The position accounts for 0.02% of the portfolio, ranked #70.

Private Capital Advisors first reported a position in REGN in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.08M in Q2 2013. 336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Private Capital Advisors held 350 shares of Regeneron Pharmaceuticals worth $218K as of Q2 2026.
Private Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.02% of Private Capital Advisors's portfolio in Q2 2026, its #70 holding.
Private Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
Private Capital Advisors's Regeneron Pharmaceuticals position peaked at $2.08M in Q2 2013.
336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Private Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.